Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study

@inproceedings{Buhl2015EfficacyAS,
  title={Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study},
  author={R. Buhl and Christian Gessner and Wolfgang Schuermann and Karin Foerster and Christian Sieder and Simone Hiltl and Stephanie Korn},
  booktitle={Thorax},
  year={2015}
}
BACKGROUND QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD. METHODS This multicentre, blinded, triple-dummy, parallel-group, non… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 41 times over the past 90 days. VIEW TWEETS